SightfileU.S. market data from official filings

TRANSMEDICS GROUP INC (TMDX)

Name: TRANSMEDICS GROUP INC (TMDX) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001756262 · EDGAR filings · Updated 2026-07-14

TRANSMEDICS GROUP INC (TMDX) has reported institutional ownership of 105.4%, with 413 institutional managers holding positions valued at $3.62B per the latest 13F reporting period.

Institutional ownership

105.4%

Institutional managers

413

Reported 13F value

$3.62B

Insider activity

38 trans.

−$3.20M net selling

Latest updates

2026-07-14 — Insider transaction reported (Form 4)
2026-07-14 — Insider transaction reported (Form 4)
2026-07-14 — Insider transaction reported (Form 4)
2026-06-17 — Insider transaction reported (Form 4)
2026-06-15 — Notice of proposed sale filed (Form 144)
2026-05-29 — SD filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, TRANSMEDICS GROUP INC has 413 institutional holders and institutional ownership of 105.4%.

Insider activity

Insiders reported 38 transactions (4 buys, 16 sells) across 12 reporting insiders, with a net reported value of −$3.20M.

Related companies

CRISPR THERAPEUTICS AG (CRSP) · ACADIA PHARMACEUTICALS INC COM (ACAD) · TWIST BIOSCIENCE CORP (TWST) · TG THERAPEUTICS INC (TGTX) · INTEGER HLDGS CORP (ITGR) · DYNE THERAPEUTICS INC (DYN)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-14.